Eskayef Pharmaceuticals Ltd.
Abemaciclib Cancer (oncology)
Originator: Verzenio · Eli Lilly and Company (Lilly USA, LLC)
| Brand | Strength | Form |
|---|---|---|
| Abeclib | 150 mg and 200 mg tablets | — |
| Abeclib | 200 mg | Tablet |
| Abeclib | 150 mg | Tablet |
Baricitinib Immunology & rheumatology
Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)
| Brand | Strength | Form |
|---|---|---|
| Baritab | 2 mg | Tablet |
Empagliflozin Diabetes & metabolic
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
| Brand | Strength | Form |
|---|---|---|
| Emazid | 10 mg, 25 mg | — |
| Emazid | 25 mg | Tablet |
| Emazid | 10 mg | Tablet |
Ibrutinib Cancer (oncology)
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
| Brand | Strength | Form |
|---|---|---|
| Ibrutab | 140 mg tablet | — |
| Ibrutab | 140 mg | Tablet |
Linagliptin Diabetes & metabolic
Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)
| Brand | Strength | Form |
|---|---|---|
| Ligazid | 5 mg tablet | — |
| Ligazid | 5 mg | Tablet |
Olaparib Cancer (oncology)
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
| Brand | Strength | Form |
|---|---|---|
| Olatab | 100 mg | Tablet |
Osimertinib Cancer (oncology)
Originator: Tagrisso · AstraZeneca
| Brand | Strength | Form |
|---|---|---|
| Osimatab | 80 mg tablet; 40 mg tablet | — |
| Osimatab | 80 mg | Tablet |
| Osimatab | 40 mg | Tablet |
Sitagliptin Diabetes & metabolic
Originator: Januvia · Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.
| Brand | Strength | Form |
|---|---|---|
| Sitazid | 50 mg and 100 mg tablets | — |
| Sitazid | 100 mg | Tablet |
| Sitazid | 50 mg | Tablet |
Tofacitinib Immunology & rheumatology
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
| Brand | Strength | Form |
|---|---|---|
| Tojak | 5 mg | Tablet |
Vildagliptin Diabetes & metabolic
Originator: Galvus · Novartis
| Brand | Strength | Form |
|---|---|---|
| Vigatin | 50 mg tablet | — |
| Vigatin | 50 mg | Tablet |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.
